

Idiopathic Pulmonary Fibrosis (IPF)

A Study to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis

A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

| | | |
|-----------------------------------|--------------------------------------|--|
| Trial Status Terminated | Trial Runs In 35 Countries | Trial Identifier NCT04552899 2020-000791-38 WA42293 |
|-----------------------------------|--------------------------------------|--|

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo in participants with idiopathic pulmonary fibrosis (IPF).

| | |
|-------------------------------------|-------------------------|
| Hoffmann-La Roche Sponsor | Phase 3 Phase |
|-------------------------------------|-------------------------|

NCT04552899 2020-000791-38 WA42293
Trial Identifiers

Eligibility Criteria:

| | | |
|----------------------|--|---------------------------------|
| Gender All | Age >=40 Years & <= 85 Years | Healthy Volunteers No |
|----------------------|--|---------------------------------|
